Navigation Links
Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
Date:7/31/2009

SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York City on Wednesday, August 5, 2009 at 1:45 p.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until August 31, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC).

NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
3. Nektar Therapeutics Reports First Quarter 2009 Financial Results
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
5. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
6. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
7. Nektar Announces Retirement of Irwin Lerner from Board of Directors
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
9. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
10. Nektar Therapeutics to Webcast R&D Day on November 12th
11. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), ... promotion of Nick Maroulis, Pharm.D. to the newly created ... , In this position, Dr. Maroulis will continue to ... directors of our multi-site pharmacies as the company expands. ... during that time he has served in many different ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Inc. announced today that it has entered into ... Biotech, Inc.  The agreement is based on Metamark,s ... specific proprietary cancer targets demonstrated to play a ... (Prognosis Determinants™). The collaboration will focus on the ...
... ALBANY, New York, December 19, 2011 ... Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices ... 78% Market Share   Published by  GBI ... Circuit (IC) Market to 2020 Programmable Logic Devices (PLD) and ...
... move past atoms in a solid, their charge distorts the ... in the lattice affects the electrons motion, in analogy to ... it. This interaction results in a thermoelectric effect that was ... known as phonon-drag, because it can be quantified from the ...
Cached Biology Technology:Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech 2ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 2ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 3ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 4A 50-year quest to isolate the thermoelectric effect is now over: Magnon drag unveiled 2
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market ... from 2014 to 2019. Although the U.S. market holds ... is expected to grow at a higher ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, ... publication of a study that pinpoints fine-scale differences in ... United States . Since immigrants first ... the United States has served as a ... illuminates how American history and the ongoing mixing of ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... For years, physicians around the world have watched as strain ... evolves resistance to drugs. Over the last few ... identify a handful of individual mutations that allow TB to ... treat it. These genetic markers serve as clues for new ...
... 2013 Amgen (NASDAQ: AMGN ) today announced ... lipoprotein cholesterol (LDL-C), or "bad" cholesterol, of up to 59 ... 12-week Phase 2 studies evaluating AMG 145 in patient populations ... antibody that inhibits PCSK9, a protein that reduces the liver,s ...
... to long-term weather forecasts that predict what the ... researchers and federal scientists have developed the first ... Northwest fisheries. "Being able to predict future ... help fisheries managers," said Samantha Siedlecki, a research ...
Cached Biology News:Researchers untangle genetics of drug resistant TB 2Researchers untangle genetics of drug resistant TB 3Researchers untangle genetics of drug resistant TB 4Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 2Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 3Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 4Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 5Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 6Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 7Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 8New ocean forecast could help predict fish habitat 6 months in advance 2New ocean forecast could help predict fish habitat 6 months in advance 3
... BioChains human adult normal Mega Western ... proprietary technology. The Mega Western Protein Arrays ... lysates from documented tissue sources. A protein ... well electrophoresesed along with a Protein molecular ...
... applications not requiring confocal, the BD Pathway ... the Pathway 435. And, the Pathway 415 ... applications require it. High-performance, ... to use the laser autofocus, camera autofocus, ...
fully automated system for the processing of microarrays on microscope slides...
... Description: ,Kit containing Dermal Fibroblasts (rabbit) ... 20% FBS and 10% DMSO at passage ... of optimized medium.This cell culture is supplied ... to provide an additional 6 months of ...
Biology Products: